Halozyme Therapeutics Inc. [NASDAQ: HALO] price surged by 1.13 percent to reach at $0.32. The company report on October 6, 2020 that Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.
Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme’s ENHANZE® drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.
A sum of 1419961 shares traded at recent session while its average daily volume was at 981.44K shares. Halozyme Therapeutics Inc. shares reached a high of $29.19 and dropped to a low of $28.175 until finishing in the latest session at $28.59.
The one-year HALO stock forecast points to a potential upside of 12.65. The average equity rating for HALO stock is currently 2.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Halozyme Therapeutics Inc. [HALO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $32.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Halozyme Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 14, 2020. While these analysts kept the previous recommendation, The Benchmark Company raised their target price to Buy. The new note on the price target was released on July 01, 2020, representing the official price target for Halozyme Therapeutics Inc. stock. Previously, the target price had yet another raise from $18 to $27, while Piper Sandler kept a Overweight rating on HALO stock. On January 09, 2020, analysts increased their price target for HALO shares from 17 to 24.
The Average True Range (ATR) for Halozyme Therapeutics Inc. is set at 0.96, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 21.18. The Price to Book ratio for the last quarter was 36.65, with the Price to Cash per share for the same quarter was set at 2.88.
HALO Stock Performance Analysis:
Halozyme Therapeutics Inc. [HALO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.74. With this latest performance, HALO shares gained by 3.85% in over the last four-week period, additionally plugging by 53.79% over the last 6 months – not to mention a rise of 79.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 61.37, with the RSI for the last a single of trading hit 66.90, and the three-weeks RSI is set at 57.44 for Halozyme Therapeutics Inc. [HALO]. The present Moving Average for the last 50 days of trading for this stock 27.73, while it was recorded at 28.35 for the last single week of trading, and 23.36 for the last 200 days.
Insight into Halozyme Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Halozyme Therapeutics Inc. [HALO] shares currently have an operating margin of -18.70 and a Gross Margin at +76.76. Halozyme Therapeutics Inc.’s Net Margin is presently recorded at -36.86.
Return on Total Capital for HALO is now -8.43, given the latest momentum, and Return on Invested Capital for the company is -19.05. Return on Equity for this stock declined to -42.41, with Return on Assets sitting at -14.36. When it comes to the capital structure of this company, Halozyme Therapeutics Inc. [HALO] has a Total Debt to Total Equity ratio set at 438.72. Additionally, HALO Total Debt to Total Capital is recorded at 81.44, with Total Debt to Total Assets ending up at 71.14. Long-Term Debt to Equity for the company is recorded at 417.42, with the Long-Term Debt to Total Capital now at 77.48.
Reflecting on the efficiency of the workforce at the company, Halozyme Therapeutics Inc. [HALO] managed to generate an average of -$547,273 per employee. Receivables Turnover for the company is 4.38 with a Total Asset Turnover recorded at a value of 0.39.Halozyme Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.30 and a Current Ratio set at 19.20.
HALO Stock EPS
With the latest financial reports released by the company, Halozyme Therapeutics Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -41.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc. go to 58.00%.
Halozyme Therapeutics Inc. [HALO] Insider Position Details
There are presently around $3,869 million, in the hands of institutional investors. The top three institutional holders of HALO stocks are: ARTISAN PARTNERS LIMITED PARTNERSHIP with ownership of 16,807,413, which is approximately 16.475% of the company’s market cap and around 1.10% of the total institutional ownership; BLACKROCK INC., holding 13,233,306 shares of the stock with an approximate value of $378.34 million in HALO stocks shares; and VANGUARD GROUP INC, currently with $373.03 million in HALO stock with ownership of nearly -6.12% of the company’s market capitalization.
Positions in Halozyme Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 168 institutional holders increased their position in Halozyme Therapeutics Inc. [NASDAQ:HALO] by around 17,571,469 shares. Additionally, 84 investors decreased positions by around 12,299,811 shares, while 27 investors held positions by with 106,986,533 shares. The mentioned changes placed institutional holdings at 136,857,813 shares, according to the latest SEC report filing. HALO stock had 71 new institutional investments in for a total of 5,108,576 shares, while 11 institutional investors sold positions of 623,976 shares during the same period.